{
  "ptid_time": "023_S_0042_2010-03-18",
  "img_path": "/data/qiuhui/data/adni/images/023_S_0042/2010-03-18/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 63,321 mm³, 64.4% above the reference mean. With a Z-score of 1.54 (93.9th percentile), this represents moderate enlargement; hippocampal volume measures 3,517 mm³, 53.5% below the reference mean. With a Z-score of -5.22 (0.0th percentile), this represents profound atrophy; whole brain volume measures 890,128 mm³, 17.5% below the reference mean. With a Z-score of -2.28 (1.1th percentile), this represents significant atrophy; entorhinal cortex volume measures 2,411 mm³, 41.2% below the reference mean. With a Z-score of -2.79 (0.3th percentile), this represents significant atrophy; fusiform gyrus volume measures 15,568 mm³, 17.4% below the reference mean. With a Z-score of -1.48 (7.0th percentile), this represents mild atrophy; middle temporal gyrus volume measures 15,500 mm³, 27.4% below the reference mean. With a Z-score of -2.46 (0.7th percentile), this represents significant atrophy. ",
  "text_data": "Age is 76.8 years. Gender is Male. Education: 18 years. MMSE: 23.0. Logical Memory: 0.0. APOEε4 alleles: 0.0. Biomarker levels: Amyloid beta: 1011.00 pg/mL (normal ); Total tau: 211.50 pg/mL (normal ); Phosphorylated tau: 18.10 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: AD.",
  "gpt_diagnosis": "**Reasoning:** The imaging data show profound hippocampal atrophy (Z-score -5.22) and significant atrophy in the entorhinal cortex and middle temporal gyrus, which are hallmark features of Alzheimer's disease (AD). Despite normal CSF biomarkers (Aβ, T-tau, P-tau), the structural changes and cognitive impairment (MMSE 23) strongly suggest neurodegenerative pathology.  \n\n**Diagnosis:** **Dementia** (likely Alzheimer’s disease, biomarker-negative atypical variant or non-AD pathology given discordant CSF results).  \n\n**Confidence:** **Medium** (high confidence in neurodegeneration, but low confidence in etiology due to normal biomarkers).  \n\n**Note:** Atypical AD or non-AD tauopathy (e.g., primary age-related tauopathy [PART]) should be considered. Further evaluation with tau-PET or neuropsychological testing for atypical syndromes may clarify.",
  "timestamp": "2025-07-26T02:28:53.647343"
}